The short version of glucagon receptor fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-04-23 and is reviewed periodically as new material appears.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
The three-receptor design places retatrutide in a distinct category relative to older incretin-based therapies. Single agonists target one receptor, and dual agonists target two. Adding a third target broadens the pharmacological footprint and introduces new trade-offs among efficacy, tolerability, and glucose control. How these trade-offs resolve in large trials is a central focus of current research.
Retatrutide is an investigational peptide studied for obesity and type 2 diabetes. It is a single synthetic molecule designed to activate three metabolic receptors simultaneously. The compound belongs to the incretin mimetic family, a group of peptides that imitate gut hormones involved in appetite and glucose control. Its research code is LY3437943, and it remains under clinical study rather than cleared for routine medical use.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Studied for metabolic indications |
| Receptor activity | GIP, GLP-1, and glucagon | Single molecule, three targets |
| Development status | Investigational | Not an approved therapy |
| Common synonym | LY3437943 | Development designation |
| Administration route | Subcutaneous injection | As used in clinical studies |
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
== Treatment == Once a nickel allergy is detected, the best treatment is avoidance of nickel-releasing items. The top 13 categories that contain nickel include beauty accessories, eyeglasses, money, cigarettes, clothes, kitchen and household, electronics and office equipment, metal utensils, aliment, jewelry, batteries, orthodontic and dental appliances, and medical equipment. Other than strict avoidance of items that release free nickel, there are other treatment options for reduction of exposure. The first step is to limit friction between skin and metallic items. Susceptible people may try to limit sweating while wearing nickel items, to reduce nickel release and thus decrease chances for developing sensitization or allergy. Another option is to shield electronics, metal devices, and tools with fabric, plastic, or acrylic coverings. There are dimethylglyoxime test kits that can be very helpful to check for nickel release from items prior to purchasing. The American Contact Dermatitis Society 'find a provider' resource can help identify clinicians with training in providing guidance lists of safe items. In addition to avoidance, healthcare providers may prescribe additional creams or medications to help relieve the skin reaction.
=== Counter Terrorist Wing === The SAS has a subunit called the Counter Terrorist Wing (CTW) that fulfils its counterterrorism (CT) role. It has previously been known as the Counter Revolutionary Warfare (CRW) Wing and special projects team. The SAS receives aviation support from No. 658 Squadron AAC to carry out their CT role. The CTW is trained in Close Quarter Battle (CQB), sniper techniques and specialises in hostage rescue in buildings or on public transport. The team was formed in the early 1970s after the Prime Minister, Edward Heath, asked the Ministry of Defence to prepare for any possible terrorist attack similar to the massacre at the 1972 Summer Olympics therefore ordering that the SAS Counter Revolutionary Warfare (CRW) wing be raised. Squadrons refresh their training every 16 months, on average. The CRW's first deployment was during the Balcombe Street siege. The Metropolitan Police had trapped a PIRA unit; it surrendered when it heard on the BBC that the SAS were being sent in. The first documented action abroad by the CRW wing was assisting the West German counter-terrorism group GSG 9 at Mogadishu. The CT role was shared amongst the squadrons, initially on a 12-month and later six-month rotation basis to ensure that all members are eventually trained in CT and CQB techniques. The SAS train for the CT role at Pontrilas Army Training Area in a facility that includes the Killing House (officially known as Close Quarter Battle House) and part of a Boeing 747 airliner that can be reconfigured to match the internal layouts of virtually any commercial aircraft.
==== Ethanol distillation ==== Graphene oxide membranes allow water vapor to pass through, but are impermeable to other liquids and gases. This phenomenon has been used for further distilling of vodka to higher alcohol concentrations, in a room-temperature laboratory, without the application of heat or vacuum as used in traditional distillation methods. Further development and commercialization of such membranes could revolutionize the economics of biofuel production and the alcoholic beverage industry.
==== Mechanisms of plasticity ==== To understand mechanisms of activity-dependent plasticity, Sur’s lab used microarray analyses of classic visual plasticity paradigms (dark-rearing and monocular deprivation during the critical period) to discover gene expression changes and microRNAs associated with cortical plasticity. They demonstrated rules of plasticity and the role of specific molecules in implementing these rules. His lab showed that neuronal plasticity is implemented by locally coordinated potentiation and depression of spines, which involves AMPA receptor redistribution via targeted expression of Arc. Together with large-scale synaptic dynamics of V1 neurons during normal development, these findings have demonstrated a fundamental principle, that Hebbian strengthening of coactive synapses and heterosynaptic weakening of adjacent synapses cooperatively mediate neuron-wide plasticity.
It was this late version (not the European ROM) that served as the basis for the port on the PC. The game was one of the first games to be released under the Disney Interactive label. By the 1996 holiday shopping season, the CD-based PlayStation and Saturn consoles had achieved a significant presence in the market, making third party publishers reluctant to spend money on expensive cartridges for consoles such as the Super NES. Because of this, Nintendo (which owned the factory where Super NES cartridges were made and thus could manufacture them more cheaply than third parties could) licensed the game from Disney Interactive and published it in North America and Europe. The game premiered for the North American market at Walt Disney World in September 1996. Three Maui Mallard kiosks were prepared in the Disney Interactive exhibit at the Innoventions plaza of EPCOT. Visitors could play the full game for an unlimited period of time and interact with Attractions Hosts and Hostesses who were available to play against them and share tips and tricks. According to composer Patrick Collins, Donald Duck's name was dropped from the North American release because the marketing team felt that "Donald Duck just isn't hip in the United States like he is in Europe".
Sources: en.wikipedia.org
Bendix first manufactured domestic radios and phonographs for the retail market after WWII as an outgrowth of its production of aircraft radios. In 1948 Bendix started to sell car radios directly to Ford and other auto manufacturers. From 1950 to 1959, Bendix made television sets. Production of radios for the retail trade grew quickly in the 1950s, but stopped quickly in the 1960s when Ford, General Motors and Chrysler started producing their own radios.
=== Digestive system === In the gut, nociceptin has been found to have varying effects on stomach and intestinal contractility while also stimulating the increased consumption of food. Additional studies have shown that nociceptin may have an effect as an anti-epileptic drug component.
Its low-energy isomeric transition, which yields a gamma-ray at ~140.5 keV, is ideal for imaging using Single Photon Emission Computed Tomography (SPECT). Several technetium isotopes, such as 94mTc, 95Tc, and 96Tc, which are produced via (p,n) reactions using a cyclotron on molybdenum targets, have also been identified as potential Positron Emission Tomography (PET) or gamma-emitting agents for medical imaging. Technetium-101 has been produced using a D-D fusion-based neutron generator from the 100Mo(n,γ)101Mo reaction on natural molybdenum and subsequent beta-minus decay of 101Mo to 101Tc. Despite its shorter half-life (14.22 minutes), 101Tc exhibits unique decay characteristics suitable for radioisotope diagnostic or therapeutic procedures, where it has been proposed that its implementation, as a supplement for dual-isotopic imaging or replacement for 99mTc, could be performed by on-site production and dispensing at the point of patient care. Technetium-99 is the most common and most readily available isotope, as it is a major fission product from fission of actinides like uranium and plutonium with a fission product yield of 6% or more, and in fact the most significant long-lived fission product. Lighter isotopes of technetium are almost never produced in fission because the initial fission products normally have a higher neutron/proton ratio than is stable for their mass range, and therefore undergo beta decay until reaching the ultimate product.
=== Predators === Newborn rattlesnakes are heavily preyed upon by a variety of species, including cats, ravens, crows, roadrunners, raccoons, opossums, skunks, coyotes, weasels, whipsnakes, kingsnakes, and racers. Young of the smaller crotaline species are frequently killed and eaten by small predatory birds, such as jays, kingfishers, and shrikes. Some species of ants in the genus Formica are known to prey upon neonates, and Solenopsis invicta (fire ants) likely do, as well. On occasion, hungry adult rattlesnakes cannibalize neonates. The small proportion (often as few as 20%) of rattlesnakes that make it to their second year are heavily preyed upon by a variety of larger predators, including coyotes, eagles, hawks, owls, falcons, feral pigs, badgers, indigo snakes, and kingsnakes. The common kingsnake (Lampropeltis getula), a constrictor, is immune to the venom of rattlesnakes and other vipers, and rattlesnakes form part of its natural diet. Rattlesnakes sense kingsnakes' presence by their odor. When they realize a kingsnake is nearby, they begin enacting a set of defensive postures known as "body bridging". Unlike its normal erect and coiled defensive-striking posture, the rattlesnake keeps its head low to the ground in an attempt to prevent the kingsnake from gaining a hold on it (the head being the first part of the rattlesnake to be ingested). The rattlesnake jerks its body about, while bridging its back upwards, forming an elevated coil that faces the kingsnake. The elevated coil is used to strike the attacker, and is also used to shield the head from the kingsnake.
Sources: en.wikipedia.org
=== Information technology === The last decade has seen a proliferation of information technology use in the planning and conduct of clinical trials. Clinical trial management systems are often used by research sponsors or CROs to help plan and manage the operational aspects of a clinical trial, particularly with respect to investigational sites. Advanced analytics for identifying researchers and research sites with expertise in a given area utilize public and private information about ongoing research. Web-based electronic data capture (EDC) and clinical data management systems are used in a majority of clinical trials to collect case report data from sites, manage its quality and prepare it for analysis. Interactive voice response systems are used by sites to register the enrollment of patients using a phone and to allocate patients to a particular treatment arm (although phones are being increasingly replaced with web-based (IWRS) tools which are sometimes part of the EDC system). While patient-reported outcome were often paper based in the past, measurements are increasingly being collected using web portals or hand-held ePRO (or eDiary) devices, sometimes wireless. Statistical software is used to analyze the collected data and prepare them for regulatory submission. Access to many of these applications are increasingly aggregated in web-based clinical trial portals.
== Uses == The plant is native to the Caribbean, where the Taíno people were the first recorded peoples to use it and cultivate it. In 1560, Jean Nicot de Villemain, then French ambassador to Portugal, brought tobacco seeds and leaves as a "wonder drug" to the French court. In 1586 the botanist Jaques Dalechamps gave the plant the name of Herba nicotiana, which was also adopted by Linné. It was considered a decorative plant at first, then a panacea, before it became a common snuff and tobacco plant. Tobacco arrived in Africa at the beginning of the 17th century. The leaf extract was a popular pest control method up to the beginning of the 20th century. In 1851, the Belgian chemist Jean Stas documented the use of tobacco extract as a murder poison. The Belgian count Hippolyte Visart de Bocarmé had poisoned his brother-in-law with tobacco leaf extract in order to acquire some urgently needed money. This was the first exact proof of alkaloids in forensic medicine. It is now commercially cultivated worldwide. All parts of the plant contain nicotine, which can be extracted and used as an insecticide. The dried leaves can also be used; they remain effective for 6 months after drying. The juice of the leaves can be rubbed on the body as an insect repellent. The leaves can be dried and chewed as an intoxicant. The dried leaves are also used as snuff or are smoked. This is the main species that is used to make cigarettes, cigars, and other products. A drying oil is obtained from the seed. Other varieties are cultivated as ornamental plants.
== General bibliography == Duane, H. D. Roller; Thilorier, M. (1952). "Thilyorier and the First Solidification of a "Permanent" Gas (1835)". Isis. 43 (2): 109–113. doi:10.1086/349402. JSTOR 227174. S2CID 144091865. Goroll, Allan H; Mulley, Albert G (2009). Primary Care Medicine: Office evaluation and management of the adult patient. Lippincott Williams & Wilkins. ISBN 978-0-7817-7513-7. Häring, Heinz-Wolfgang (2008). Industrial Gases Processing. Christine Ahner. Wiley-VCH. ISBN 978-3-527-31685-4. Retrieved 2009-07-31. Housecroft, Catherine; Sharpe, Alan G (2001). Inorganic chemistry. Harlow: Prentice Hall. p. 410. ISBN 978-0-582-31080-3. Retrieved 2009-07-31. Keyes, Conrad G (2006). Guidelines for Cloud Seeding to Augment Precipitation. American Society of Civil Engineers. ASCE Publications. ISBN 978-0-7844-0819-3. Verma, N. K.; Khanna, S. K.; Kapila, B. (2008). Comprehensive Chemistry for Class XI. New Delhi: Laxmi Publications. ISBN 978-81-7008-596-6. Retrieved 2009-07-31. McCarthy, Robert E. (1992). Secrets of Hollywood Special Effects. Boston: Focal Press. ISBN 978-0-240-80108-7. Mitra, Somenath (April 2004). Sample Preparation Techniques in Analytical Chemistry. Wiley-IEEE. ISBN 978-0-471-32845-2. Retrieved 2009-07-31. Treloar, Roy D. (2003). Plumbing Encyclopaedia (3rd ed.). Wiley-Blackwell. p. 175. ISBN 978-1-4051-0613-9. Retrieved 2009-07-31. Yaws, Carl (2001). Matheson Gas Data Book (7th ed.). McGraw-Hill Professional. ISBN 978-0-07-135854-5. 982 pages. Retrieved 2009-07-27.
Sources: en.wikipedia.org
It is described as a single molecule that acts at three receptors: the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This triple activity distinguishes it from agents that target one or two of these pathways.
It is characterized in the literature as an investigational agent under clinical study. Approval status depends on jurisdiction, and readers should check current regulatory information rather than assume availability.
The combination is intended to pair appetite-related and glucose-related effects with mechanisms that increase energy expenditure. Whether the combined profile offers advantages over simpler agonists is the subject of ongoing research.
It is a synthetic peptide classified as a triple receptor agonist. It engages the GLP-1, GIP, and glucagon receptors at once. It is investigated for metabolic and weight-related conditions rather than approved for general use.